FY2026 EPS Estimates for Progyny Lifted by Leerink Partnrs

Progyny, Inc. (NASDAQ:PGNY) – Research analysts at Leerink Partnrs boosted their FY2026 earnings estimates for shares of Progyny in a report released on Tuesday, July 8th. Leerink Partnrs analyst M. Cherny now anticipates that the company will post earnings of $0.98 per share for the year, up from their prior estimate of $0.94. Leerink Partnrs has a “Strong-Buy” rating on the stock. The consensus estimate for Progyny’s current full-year earnings is $0.60 per share.

Progyny (NASDAQ:PGNY) last posted its quarterly earnings data on Thursday, May 8th. The company reported $0.17 earnings per share for the quarter, missing analysts’ consensus estimates of $0.45 by ($0.28). The company had revenue of $324.04 million for the quarter, compared to the consensus estimate of $307.86 million. Progyny had a net margin of 4.33% and a return on equity of 10.90%. The firm’s quarterly revenue was up 16.5% on a year-over-year basis. During the same period last year, the business earned $0.17 EPS.

Several other research analysts have also recently issued reports on the company. Canaccord Genuity Group dropped their target price on Progyny from $23.00 to $21.00 and set a “hold” rating on the stock in a research report on Monday, May 12th. Leerink Partners upgraded shares of Progyny from a “market perform” rating to an “outperform” rating and set a $28.00 target price for the company in a research report on Tuesday. Finally, BTIG Research upgraded shares of Progyny from a “neutral” rating to a “buy” rating and set a $28.00 target price for the company in a research report on Monday, March 31st. Five research analysts have rated the stock with a hold rating, six have assigned a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $24.09.

Progyny Stock Performance

NASDAQ PGNY opened at $23.61 on Thursday. Progyny has a one year low of $13.39 and a one year high of $30.42. The stock has a 50-day moving average of $21.81 and a 200 day moving average of $21.47. The company has a market capitalization of $2.02 billion, a price-to-earnings ratio of 41.42, a PEG ratio of 2.50 and a beta of 1.31.

Insider Activity at Progyny

In other Progyny news, Director Cheryl Scott sold 2,675 shares of the firm’s stock in a transaction dated Wednesday, June 11th. The stock was sold at an average price of $22.07, for a total value of $59,037.25. Following the completion of the sale, the director owned 14,112 shares of the company’s stock, valued at approximately $311,451.84. This trade represents a 15.93% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Corporate insiders own 9.40% of the company’s stock.

Institutional Trading of Progyny

Several large investors have recently bought and sold shares of PGNY. Signaturefd LLC raised its stake in shares of Progyny by 1,355.0% in the fourth quarter. Signaturefd LLC now owns 1,455 shares of the company’s stock worth $25,000 after purchasing an additional 1,355 shares during the last quarter. BI Asset Management Fondsmaeglerselskab A S acquired a new stake in Progyny during the 1st quarter valued at approximately $44,000. Militia Capital Partners LP lifted its stake in Progyny by 100.0% during the 1st quarter. Militia Capital Partners LP now owns 2,000 shares of the company’s stock valued at $45,000 after acquiring an additional 1,000 shares during the period. Natixis acquired a new stake in Progyny during the 4th quarter valued at approximately $69,000. Finally, Brooklyn Investment Group lifted its stake in Progyny by 5,216.4% during the 1st quarter. Brooklyn Investment Group now owns 3,243 shares of the company’s stock valued at $72,000 after acquiring an additional 3,182 shares during the period. Hedge funds and other institutional investors own 94.93% of the company’s stock.

About Progyny

Progyny, Inc, a benefits management company, specializes in fertility and family building benefits solutions in the United States. Its fertility benefits solution includes differentiated benefits plan design, personalized concierge-style member support services, and selective network of fertility specialists.